奥氮平与喹硫平对小儿精神障碍患者不良反应及睡眠质量的影响
|
摘要
目的:探究奥氮平与喹硫平对小儿精神障碍患者不良反应及睡眠质量的影响。方法:选取2016年1月至2017年9月北京大学第六医院收治的儿童青少年精神障碍患者78例作为研究对象,采用随机数字表法分为奥氮平组和喹硫平组,分别实施相应的药物治疗,试验周期为4周,比较2组患者治疗前后匹兹堡睡眠质量指数(PSQI)量表评分及治疗后不良反应的发生率。结果:奥氮平组患者治疗后不良反应的发生率显著高于喹硫平组,同时患者的不良反应中心动过缓、体质量增加、嗜睡、低血压的发生率均高于喹硫平组;喹硫平组患者心动过速的发生率显著高于奥氮平组,差异无统计学意义(P> 0. 05); 2组患者治疗前基线匹兹堡睡眠质量指数(PSQI)量表评分比较,差异无统计学意义(P> 0. 05),具有可比性;2组患者治疗前的PSQI基线评分均显著高于治疗后PSQI评分,差异有统计学意义(P <0. 05); 2组患者治疗后组间PSQI评分比较,差异无统计学意义(P> 0. 05)。结论:奥氮平与喹硫平对小儿精神障碍患者不良反应比较差异无统计学意义,同时2种药物在改善儿童青少年睡眠质量方面疗效佳且效能大致相同。
Objective: To investigate the effects of olanzapine and quetiapine on adverse reactions and sleep quality in children with mental disorders. Methods: A total of 78 children and adolescents with mental disorders in our hospital were enrolled from January 2016 to September 2017. They were randomly divided into olanzapine group and quetiapine group by random number table. Olanzapine group was given oral olanzapine tablets,while quetiapine group was given oral quetiapine tablets. The test period was 4 weeks,and the Pittsburgh Sleep Quality Index( PSQI) scale score and the incidence of adverse reactions after treatment were compared before and after treatment. Results: The incidence of adverse reactions after treatment in olanzapine group was significantly higher than those in quetiapine group. At the same time,the incidence of adverse reactions,weight gain,lethargy and hypotension were higher in olanzapine group than in quetiapine group. The incidence of tachycardia in quetiapine group was significantly higher than that of olanzapine group,and there was no significant difference between the two groups( P > 0. 05). And there was no significant difference in the baseline Pittsburgh Sleep Quality Index( PSQI) scale between the two groups( P > 0. 05). The scores of PSQI before treatment were significantly higher than after treatment( P < 0. 05). There was no significant difference in PSQI score between the two groups after treatment( P > 0. 05). Conclusion: There is no significant difference in the adverse reactions between olanzapine and quetiapine in children with mental disorders. At the same time,the two drugs are effective and have almost the same efficacy in improving the quality of sleep in children and adolescents.
Objective: To investigate the effects of olanzapine and quetiapine on adverse reactions and sleep quality in children with mental disorders. Methods: A total of 78 children and adolescents with mental disorders in our hospital were enrolled from January 2016 to September 2017. They were randomly divided into olanzapine group and quetiapine group by random number table. Olanzapine group was given oral olanzapine tablets,while quetiapine group was given oral quetiapine tablets. The test period was 4 weeks,and the Pittsburgh Sleep Quality Index( PSQI) scale score and the incidence of adverse reactions after treatment were compared before and after treatment. Results: The incidence of adverse reactions after treatment in olanzapine group was significantly higher than those in quetiapine group. At the same time,the incidence of adverse reactions,weight gain,lethargy and hypotension were higher in olanzapine group than in quetiapine group. The incidence of tachycardia in quetiapine group was significantly higher than that of olanzapine group,and there was no significant difference between the two groups( P > 0. 05). And there was no significant difference in the baseline Pittsburgh Sleep Quality Index( PSQI) scale between the two groups( P > 0. 05). The scores of PSQI before treatment were significantly higher than after treatment( P < 0. 05). There was no significant difference in PSQI score between the two groups after treatment( P > 0. 05). Conclusion: There is no significant difference in the adverse reactions between olanzapine and quetiapine in children with mental disorders. At the same time,the two drugs are effective and have almost the same efficacy in improving the quality of sleep in children and adolescents.
引文
[1]黄海兰.儿童青少年精神障碍流行病学和相关因素研究[J].中国卫生产业,2017,14(24):4-5,8.
[2]闫俊娟,崔永华.北京安定医院住院儿童青少年精神疾病患者抗精神病药临床使用情况分析[J].临床精神医学杂志,2017,27(1):15-18.
[3]黎艳华,李乐之,罗学荣,等.儿童青少年精神障碍流行病学及相关因素研究[J].神经疾病与精神卫生,2015,15(1):84-87.
[4]张鸿燕.新剂型非典型抗精神病药富马酸喹硫平缓释片的研究进展[J].中国新药杂志,2015,24(1):35.
[5]Olfson M,King M,Schoenbaum M. Treatment of young people with antipsychotic medication in the United States[J]. JAMA Psychiatry,2015,72(9):867-874.
[2]闫俊娟,崔永华.北京安定医院住院儿童青少年精神疾病患者抗精神病药临床使用情况分析[J].临床精神医学杂志,2017,27(1):15-18.
[3]黎艳华,李乐之,罗学荣,等.儿童青少年精神障碍流行病学及相关因素研究[J].神经疾病与精神卫生,2015,15(1):84-87.
[4]张鸿燕.新剂型非典型抗精神病药富马酸喹硫平缓释片的研究进展[J].中国新药杂志,2015,24(1):35.
[5]Olfson M,King M,Schoenbaum M. Treatment of young people with antipsychotic medication in the United States[J]. JAMA Psychiatry,2015,72(9):867-874.